Ishikawa T - Search Results

1

Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.

Ohtaki N, Takahashi H, Kaneko K, Gomi Y, Ishikawa T, Higashi Y, Kurata T, Sata T, Kojima A. Ohtaki N, et al. Among authors: ishikawa t. Vaccine. 2010 Sep 14;28(40):6588-96. doi: 10.1016/j.vaccine.2010.07.055. Epub 2010 Aug 1. Vaccine. 2010. PMID: 20678586

2

Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine.

Kojima A, Yasuda A, Asanuma H, Ishikawa T, Takamizawa A, Yasui K, Kurata T. Kojima A, et al. Among authors: ishikawa t. J Virol. 2003 Aug;77(16):8745-55. doi: 10.1128/jvi.77.16.8745-8755.2003. J Virol. 2003. PMID: 12885894 Free PMC article.

3

Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone.

Mutoh E, Ishikawa T, Takamizawa A, Kurata T, Sata T, Kojima A. Mutoh E, et al. Among authors: ishikawa t. Vaccine. 2004 Jun 30;22(20):2599-608. doi: 10.1016/j.vaccine.2003.12.008. Vaccine. 2004. PMID: 15193385

4

Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus.

Takahashi H, Ohtaki N, Maeda-Sato M, Tanaka M, Tanaka K, Sawa H, Ishikawa T, Takamizawa A, Takasaki T, Hasegawa H, Sata T, Hall WW, Kurata T, Kojima A. Takahashi H, et al. Among authors: ishikawa t. Microbes Infect. 2009 Nov;11(13):1019-28. doi: 10.1016/j.micinf.2009.07.009. Epub 2009 Aug 7. Microbes Infect. 2009. PMID: 19647801 Free article.

5

Purification and concentration of non-infectious West Nile virus-like particles and infectious virions using a pseudo-affinity Cellufine Sulfate column.

Ohtaki N, Takahashi H, Kaneko K, Gomi Y, Ishikawa T, Higashi Y, Todokoro M, Kurata T, Sata T, Kojima A. Ohtaki N, et al. Among authors: ishikawa t. J Virol Methods. 2011 Jun;174(1-2):131-5. doi: 10.1016/j.jviromet.2011.03.021. Epub 2011 Apr 1. J Virol Methods. 2011. PMID: 21440004

6

Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.

Ainai A, Tamura S, Suzuki T, Ito R, Asanuma H, Tanimoto T, Gomi Y, Manabe S, Ishikawa T, Okuno Y, Odagiri T, Tashiro M, Sata T, Kurata T, Hasegawa H. Ainai A, et al. Among authors: ishikawa t. J Med Virol. 2012 Feb;84(2):336-44. doi: 10.1002/jmv.22273. J Med Virol. 2012. PMID: 22170556

7

Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated).

Kikukawa A, Gomi Y, Akechi M, Onishi T, Manabe S, Namazue J, Fuke I, Ishikawa T, Okuno Y, Ueda S. Kikukawa A, et al. Among authors: ishikawa t. Vaccine. 2012 Mar 16;30(13):2329-35. doi: 10.1016/j.vaccine.2012.01.054. Epub 2012 Jan 31. Vaccine. 2012. PMID: 22306856 Clinical Trial.

8

DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine.

Gomi Y, Ozaki T, Nishimura N, Narita A, Suzuki M, Ahn J, Watanabe N, Koyama N, Ushida H, Yasuda N, Nakane K, Funahashi K, Fuke I, Takamizawa A, Ishikawa T, Yamanishi K, Takahashi M. Gomi Y, et al. Among authors: ishikawa t. Vaccine. 2008 Oct 16;26(44):5627-32. doi: 10.1016/j.vaccine.2008.07.069. Epub 2008 Aug 14. Vaccine. 2008. PMID: 18706951

9

Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.

Okamoto S, Yoshii H, Matsuura M, Kojima A, Ishikawa T, Akagi T, Akashi M, Takahashi M, Yamanishi K, Mori Y. Okamoto S, et al. Among authors: ishikawa t. Clin Vaccine Immunol. 2012 Jan;19(1):17-22. doi: 10.1128/CVI.05412-11. Epub 2011 Nov 16. Clin Vaccine Immunol. 2012. PMID: 22089248 Free PMC article.

10

Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.

Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, Ishikawa T, Akagi T, Akashi M, Okuno Y, Mori Y, Yamanishi K. Okamoto S, et al. Among authors: ishikawa t. Clin Vaccine Immunol. 2012 Jul;19(7):979-90. doi: 10.1128/CVI.00016-12. Epub 2012 May 2. Clin Vaccine Immunol. 2012. PMID: 22552600 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,836 results

Search Page

Filters